Collectively, these observations position TMEM106A as a companion biomarker candidate for risk stratification and PD‐1–axis nomination in IDH‐wildtype glioma, with cytokine‐pathway co‐targeting and mutant‐p53 strategies as prioritized avenues. Here, TP53 is linked to glioma.